Boryung seeking sales of 100 billion won with new antihypertensive
Published: 2010-09-14 06:59:00
Updated: 2010-09-14 06:59:00
Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said on September 9 that its newly approved fimasartan, a new angiotensin II receptor blocker, is expected to generate 100 billion won ($87 million) in domestic sales within the next five years.
This already large mar...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
